Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Debra Patt, MD, PhD, MBA, executive vice president of policy and strategic initiatives and director of public policy at Texas Oncology, joins hosts Emeline Aviki, MB, MBA, medical director and attending surgeon at NYU Langone Perlmutter Cancer Center, and Stephen, MD, MBA, chief medical officer at Tennessee Oncology, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Patt is a policy and physician expert, breast cancer specialist, and board member of the Community Oncology Alliance and American Society of Clinical Oncology. Her in-depth conversation with Aviki and Schleicher addresses several important issues currently affecting high-quality oncology care: most important, the current drug shortage, and the economics that made it a problem, innovative ways to fix it, and economic solutions to prevent it from perpetuating.
They also discuss the instability of drug pricing—wholesale acquisition cost vs average sales price—the relationship between cancer and aging, pharmacy benefits managers and how they have affected the price of cancer care, and facilitating meaningful change for patients.
For audio only:
Listen above or on one of these podcast services:
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More